Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Zymeworks ( (ZYME) ) is now available.
Zymeworks Inc. announced it will report its second quarter 2025 financial results on August 7, 2025, followed by a conference call to discuss the results and provide a corporate update. The company is also participating in several investor conferences in July and August, highlighting its active engagement with the investment community. This announcement underscores Zymeworks’ ongoing efforts to maintain transparency with stakeholders and its strategic positioning within the biotechnology industry.
The most recent analyst rating on (ZYME) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks’ overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and cash flow challenges. However, positive sentiment from the latest earnings call, driven by revenue growth and strategic partnerships, provides some optimism. Technical indicators show a positive short-term trend, but valuation remains unattractive due to ongoing losses.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company aims to improve the standard of care for difficult-to-treat diseases such as cancer, inflammation, and autoimmune diseases. Zymeworks utilizes its proprietary Azymetric™ technology to engineer differentiated antibody-based therapeutic candidates, including zanidatamab, which has received various regulatory approvals for treating HER2-positive biliary tract cancer.
Average Trading Volume: 470,306
Technical Sentiment Signal: Strong Buy
Current Market Cap: $904.9M
Learn more about ZYME stock on TipRanks’ Stock Analysis page.